|
|
NEW ON THE MARKET
|
|
A new anti-hypertensive drug: aliskiren (RASILEZ)
|
|
|
THERAPY FROM A CRITICAL VIEWPOINT
|
|
Thiazide diuretics: first choice for diabetic patients with hypertension
What is the evidence for hip protectors?
|
|
|
a-t READERS' QUESTIONS AND COMMENTS
|
|
Testosterone patch INTRINSA for women after surgical castration?
ACE-inhibitors for coronary heart disease even without heart failure?
Strontium ranelate (PROTELOS): prevention of non-vertebral fractures proven?
Janssen-Cilag's comment on paliperidone (INVEGA)
|
|
|
IN BRIEF
|
|
QTc-prolongation: clobutinol antitussives (e.g. SILOMAT) off market
Call for a register for doctor's fees from the industry
|
|
|
CURRENT ADR NETWORK REPORT
|
|
Montelukast (SINGULAIR) and depression
|
|
|
SIDE EFFECTS
|
|
Valproate (e.g. ORFIRIL): pubertas praecox and endocrine effects
Botulinum toxin (e.g. BOTOX): dysphagia, myasthenia and death
|
|